Flerie's TOL2 drug enters pivotal trials as bonus shares boost research funding

Flerie has reached a key moment in its growth, with major developments in both corporate and clinical areas. The company's flagship drug candidate, TOL2, is now advancing into a critical phase of testing for myasthenia gravis. At the same time, shareholders will soon receive bonus shares as part of a strategic move to fund further research instead of issuing dividends. The company's annual general meeting in March 2026 approved a bonus share issue, setting May 18 as the record date for allocations. Shareholders who previously received Flerie stock at an 88:1 ratio after the merger with Toleranzia AB will get additional free shares on that day. This date also marks the technical processing of these allocations in their accounts.

Flerie has chosen to reinvest profits rather than pay dividends for the last fiscal year. The funds will support the ongoing development of TOL2, a drug designed to treat myasthenia gravis, a rare autoimmune disorder. The treatment is currently in Phase I/IIa clinical trials, assessing its safety, tolerability, and early signs of effectiveness. Trials for TOL2 are underway across several European countries, including Germany and Sweden. While the exact number of study centres in Germany remains undisclosed, market analysts see the drug as a potential game-changer for patients with myasthenia gravis. The company has also completed the full integration of former Toleranzia AB into its operations, consolidating its research pipeline.

The bonus share distribution on May 18 will provide Flerie with extra capital to push TOL2 through its next development stages. With trials progressing in key European markets, the drug's performance in coming months will be closely watched. Shareholders, meanwhile, will see their holdings increase as the company focuses on long-term growth over short-term payouts.